

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

|                        |                |
|------------------------|----------------|
| Confirmation Number    | 5531           |
| Application Number     | 10/823,834     |
| Filing Date            | April 14, 2004 |
| First Named Inventor   | Fennimore      |
| Group Art Unit         | 1615           |
| Examiner Name          | C. A. Azpuru   |
| Attorney Docket Number | CRD5078USNP    |

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published  | T <sup>2</sup> |
|----------------------|-----------------------|---|----------------|
|                      |                       | <b>BEUTLER, E.</b> "Cladribine (2-chlorodeoxyadenosine)", <i>The Lancet</i> , Vol. 340, p. 952 (October 1992)   |                |
|                      |                       | <b>BREHM, B.</b> , et al. " $\beta$ -Blockers of the Third Generation Inhibit Endothelin-1 Liberation, mRNA production and Proliferation of Human Coronary Smooth Muscle and Endothelial Cells", <i>Journal of Cardiovascular Pharmacology</i> , 36 (Suppl. 1):S401-S403 (2000)                         |                |
|                      |                       | <b>BREHM, B.</b> , et al. "Chronically Elevated Endothelin-1 Concentrations Modulate the $\beta$ -Adrenergic Receptor System In Vitro and In Vivo", <i>Journal of Cardiovascular Pharmacology</i> , 36 (Suppl. 1):S157-159 (2000)   |                |
|                      |                       | <b>CARSON, D.</b> , et al. "DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death", <i>Experimental Cell Research</i> 164 p. 273-281 (1986)  |                |
|                      |                       | <b>CLOWES and SCHWARTZ</b> , "Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery", <i>Cir. Res.</i> 56: 139-145 (1985)   |                |
|                      |                       | <b>DEROANNE, C.</b> , et al. "Histone Deacetylases Inhibitors as Anti-Angiogenic Agents Altering Vascular endothelial Growth Factor Signaling", <i>Oncogene</i> 21, p. 427-436 (2002)   |                |
|                      |                       | <b>LANG, R.</b> , et al. "Effects of Okadaic Acid and ATP <sub>S</sub> on Cell Length and CA <sup>2+</sup> -Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci", <i>Br. J. Pharmacol.</i> 104, p. 331-336 (1991)  |                |
|                      |                       | <b>SERRUYS, P.</b> et al. "Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized double-Blind Placebo-Controlled Trial", <i>Circulation of the Journal of the American Heart Association</i> , 88 p. 1588-1601 (1993) |                |
|                      |                       | <b>SERRUYS, P.</b> , et al. "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", <i>Circulation of the American Heart Association</i> , Volume 93(3) p. 412-422 (1996)  |                |
|                      |                       |   |                |
|                      |                       |   |                |
|                      |                       |   |                |

|                        |                    |
|------------------------|--------------------|
| Examiner/<br>Signature | Date<br>Considered |
|------------------------|--------------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/B1Q

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Confirmation Number 5531  
Application Number 10/823,834  
Filing Date April 14, 2004  
First Named Inventor Fennimore  
Group Art Unit 1615  
Examiner Name C. A. Azpuru  
Altform Docket Number CRD50781USP

|                       |                    |  |
|-----------------------|--------------------|--|
| Examiner<br>Signature | Date<br>Considered |  |
|-----------------------|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.  Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.